Mirae Asset Global Investments Co. Ltd. Purchases 126,572 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 126,572 shares of the biopharmaceutical company’s stock, valued at approximately $95,976,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. Legal & General Group Plc acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $473,872,000. Bank of New York Mellon Corp acquired a new stake in Regeneron Pharmaceuticals during the second quarter worth about $472,950,000. Deutsche Bank AG acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $323,249,000. Finally, Man Group plc acquired a new position in Regeneron Pharmaceuticals in the second quarter valued at approximately $272,460,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, insider Andrew Murphy sold 4,147 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the completion of the sale, the insider owned 47,833 shares of the company’s stock, valued at approximately $36,960,559.10. This represents a 7.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,093 shares of company stock valued at $6,506,845. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 13.3%

Shares of REGN stock opened at $927.89 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $935.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock’s fifty day moving average is $793.30 and its two-hundred day moving average is $738.05. The firm has a market capitalization of $95.54 billion, a P/E ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same period in the prior year, the business earned $11.83 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on REGN shares. Robert W. Baird upped their price objective on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the stock a “neutral” rating in a research report on Friday, July 31st. HSBC lifted their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Leerink Partners boosted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Sanford C. Bernstein increased their price target on shares of Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a “market perform” rating in a report on Friday, August 14th. Finally, Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $850.83.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.